Number of partners
President and CEO
Partner, CTI Life Sciences
New commercialization models involving partnerships between big pharma, small biotechs, and universities are becoming the norm for advancing promising drug discoveries from lab to bedside. The NEOMED Institute is based in two integrated R&D facilities: one in Technoparc Montréal’s Saint-Laurent Campus, specializing in small molecule therapeutics, and one in Laval, specializing in the development of biologics and vaccines. NEOMED is leveraging these state-of-the-art R&D facilities and their multi-tenant, open-access drug development hub, along with additional funding from the Quebec Government, GlaxoSmithKline (GSK), AstraZeneca, Pfizer, Johnson & Johnson Innovation and Purdue Pharma to advance outstanding Canadian discoveries towards successful commercialization.
NEOMED identifies promising drug discovery projects emerging from academia and small- and medium-sized enterprises (SMEs). It then works closely with project originators, academic laboratories and contract research organizations to advance the research to the all-important proof-of-concept stage in humans. This approach improves the bottom line for Canadian SMEs, while strengthening the network of service and clinical companies based in Canada. It also creates strong ties between SMEs and international pharmaceutical companies, and new opportunities to conduct clinical trials of new drugs in Canada.